StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX)

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report released on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

CPIX stock opened at $1.58 on Thursday. The company has a 50 day moving average price of $1.78 and a 200 day moving average price of $1.86. Cumberland Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $2.36. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.28 and a quick ratio of 1.11. The stock has a market capitalization of $22.40 million, a PE ratio of -3.59 and a beta of 0.17.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%. The firm had revenue of $9.35 million for the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bank of New York Mellon Corp bought a new position in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 75,268 shares of the specialty pharmaceutical company’s stock, valued at approximately $142,000. Bank of New York Mellon Corp owned 0.52% of Cumberland Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.